ReNerve Limited (ASX:RNV)

Market Cap	14.13M -5.6%
Revenue (ttm)	333.21K +38.1%
Net Income	-4.61M
EPS	-0.03
Shares Out	172.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	50,295
Open	0.0890
Previous Close	0.0860
Day's Range	0.0820 - 0.0890
52-Week Range	0.0690 - 0.2200
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About ReNerve

ReNerve Limited, a medical device company, develops tissue-based products for peripheral nerve repair and replacement, and other related soft tissue surgical procedures. It develops NervAlign Nerve Cuff, a bioabsorbable protective wrap used to protect repaired nerves; and NervAlign bionic nerve and NervAlign Nerve Graft, an off-the-shelf, ready to use nerve structure for challenging nerve repairs. The company also offers deep dermal tissue product, a deep dermal product used in the repair of reconstructive and cosmetic surgical cases; amniotic ...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RNV

Financial Performance

In fiscal year 2025, ReNerve's revenue was 271,707, an increase of 53.18% compared to the previous year's 177,373. Losses were -3.73 million, 25.1% more than in 2024.

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Jun 19, 2026

Data Sources Report a data error